Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I clinical trial of ShigETEC

Trial Profile

Phase I clinical trial of ShigETEC

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escherichia coli/Shigella oral vaccine-Eveliqure (Primary)
  • Indications Traveller's diarrhoea
  • Focus Adverse reactions; First in man
  • Sponsors Eveliqure Biotechnologies
  • Most Recent Events

    • 14 Sep 2020 New trial record
    • 10 Sep 2020 According to an Eveliqure Biotechnologies media release, the company announced today the award of a grant from Horizon2020- the European Union's Research and Innovation programme that supports first-in-man studies of the ShigETEC vaccine. The project will run for 5 years and will cover the manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity studies in two different populations, adults in Europe and children in Bangladesh.
    • 09 Sep 2020 According to an Eveliqure Biotechnologies pipeline, this trial is due to start in H1 2020. (https://www.eveliqure.com/strategy)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top